ArticleToxics2025
Construction and Application of Indirect Competitive Enzyme-Linked Immunosorbent Assay for Acetamiprid in Traditional Chinese Medicine.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contamination of traditional Chinese medicines (TCMs) with neonicotinoid pesticides, notably acetamiprid (ACE), poses a significant challenge to product safety. Conventional detection methods are often hampered by operational complexity, prolonged analysis times, and dependence on sophisticated instrumentation, rendering them impractical for rapid on-site screening. To address these limitations, an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) was developed for the efficient quantification of ACE residue in TCM matrices. A monoclonal antibody-based ic-ELISA was developed through the synthesis of an ACE antigen. Critical assay parameters-including coated antigen concentration, antibody dilution ratio, and blocking buffer composition-were systematically optimized. The validated protocol was subsequently applied to ACE detection in five representative TCMs. The sensitivity (IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.